TokenPost·

Chemomab Therapeutics Posts $5.1 Million Third-Quarter Net Loss

Your call?

The loss was less than $0.01 per basic and diluted ordinary share. Cash, cash equivalents and short-term bank deposits totaled $4.7 million as of Sept. 30, 2026.

Share

More news